Marshall Wace
FHTX icon

Marshall Wace’s Foghorn Therapeutics FHTX Stock Holding History

Marshall Wace’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,893
Closed -$156K – 3363
2025
Q4 		$156K Buy
+28,893
New +$131K ﹤0.01% 2643
2024
Q2 		– Sell
-36,526
Closed -$245K – 2671
2024
Q1 		$245K Buy
+36,526
New +$203K ﹤0.01% 2174

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Marshall Wace's FHTX Position: Q1 2026 in Review

Marshall Wace sold out of Foghorn Therapeutics (FHTX) in Q1 2026, closing a stake of 28,893 shares — an estimated $156K sold.

Marshall Wace first reported a position in FHTX in Q1 2024 and held it in 2 quarters. The position peaked at $245K in Q1 2024. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Marshall Wace reported no remaining Foghorn Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 28,893 Foghorn Therapeutics shares in Q1 2026, an estimated $156K.
  • Marshall Wace first reported a position in Foghorn Therapeutics in Q1 2024 and held it in 2 quarters.
  • Marshall Wace's Foghorn Therapeutics position peaked at $245K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.